Finally we used CD-spectroscopy to elucidate the absolute
configuration. The CD-spectra of fumimycin was simulated
using time-dependent density functional theory (TDDFT)11 as
12
implemented in TURBOMOLE. z The characteristic strong band
at 255 nm arises from an n - p* transition in the fumaric
acid side chain which is chirally perturbed by the lactone
carbonyl chromophore (see ESIw). The simulated curve of
the (R)-enantiomer matches with the measured CD-curve of
the synthesized (+)-fumimycin (Fig. 3). It can be concluded
that the natural (ꢀ)-fumimycin bears (S)-configuration.
The enantioselective 1,2-addition of methyl Grignard reagents,
employing quinine as chiral additive, yielded a-trisubstituted
amines in up to 65% ee. This novel methodology13 and enantio-
enrichment by recrystallisation enabled the first asymmetric
synthesis of (+)-fumimycin in 90% ee. The absolute configu-
ration of (+)-fumimycin was assigned to be (R) using
CD-spectroscopy and TDDFT-calculations.
Scheme 3 Precursors of fumimycin, whose structures were confirmed
by X-ray analysis.
therefore the unnatural enantiomer. The natural enantiomer
should be accessible by employing quinidine instead of quinine
as additive (see Table 3). To determine the absolute configu-
ration, crystallisation of several intermediates were attempted.
Thus, the structures of the ketimines 4 and 7 could be
confirmed, as well as the structures of the a-trisubstituted
amines 8 and 9 (Scheme 3). However, enantioenriched samples
of 8 and 9 furnished only racemic monocrystals (see ESIw).
P.G. acknowledges a scholarship of the German Business
Foundation, F.F. acknowledges support by the NSF, grant
no. CHE-0840513.
Notes and references
z The PBE0 hybrid functional was used with SVPD-basic sets, the
structure was optimized using PBE0/TZVP. Solvent effects were
treated by the COSMO continuum solvation model. See ESIw for
further details.
1 S. Brase, A. Encinas, J. Keck and C. F. Nising, Chem. Rev., 2009,
¨
109, 3903–3990.
2 Y.-J. Kwon, M.-J. Sohn, C.-J. Zheng and W.-G. Kim, Org. Lett.,
2007, 9, 2449–2451.
3 Z. Yuan, J. Trias and R. J. White, Drug Discovery Today, 2001, 6,
954–961; D. R. P. Guay, Ther. Clin. Risk Manage., 2007, 3,
513–525.
4 P. J. Gross and S. Brase, Chem.–Eur. J., 2010, DOI: 10.1002/
¨
chem.201001036.
5 P. J. Gross, C. E. Hartmann, M. Nieger and S. Brase, J. Org.
Chem., 2010, 75, 229–232.
¨
6 C. Lauzon and A. B. Charette, Org. Lett., 2006, 8, 2743–2745;
P. Fu, M. L. Snapper and A. H. Hoveyda, J. Am. Chem. Soc.,
2008, 130, 5530–5541.
7 G. Alvaro and D. Savoia, Synlett, 2002, 1437–2096; J. A. Ellman,
T. D. Owens and T. P. Tang, Acc. Chem. Res., 2002, 35, 984–995;
D. M. Spero and S. R. Kapdia, J. Org. Chem., 1997, 62,
5537–5541.
8 Y. Kohmura and T. Mase, J. Org. Chem., 2004, 69, 6329–6334;
P. Wipf and C. R. J. Stephenson, Org. Lett., 2003, 5, 2449–2452.
9 M. A. Huffman, N. Yasuda, A. E. DeCamp and E. J. J. Grabowski,
J. Org. Chem., 1995, 60, 1590–1594.
10 H. Buschmann, H.-D. Scharf, N. Hoffmann and P. Esser, Angew.
Chem., Int. Ed. Engl., 1991, 30, 477–515.
11 F. Furche, R. Ahlrichs, C. Wachsmann, E. Weber, A. Sobanski,
F. Vogtle and S. Grimme, J. Am. Chem. Soc., 2000, 122,
¨
1717–1724.
12 TURBOMOLE V6.2, Turbomole GmbH, Karlsruhe, 2009,
13 For recent examples of non-asymmetric, asymmetric or diastereo-
selective 1,2-addition reaction towards iminoesters: (a) J. S. Dickstein,
M. W. Fennie, A. L. Norman, B. J. Paulose and M. C. Kozlowski,
J. Am. Chem. Soc., 2010, 132, 15794–15795 and references therein;
(b) R. Almansa, D. Guijarro and M. Yus, Tetrahedron: Asymmetry,
2007, 18, 2828–2840; (c) R. Almansa, D. Guijarro and M. Yus,
Tetrahedron Lett., 2009, 50, 4188–4190.
Fig. 3 Simulated CD-curve of (R)-fumimycin (upper panel) and
measured CD-curve of (+)-fumimycin (lower panel).
c
This journal is The Royal Society of Chemistry 2010
Chem. Commun., 2010, 46, 9215–9217 9217